Lyngby, Denmark
Biotechnology
www.symphogen.com
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Dr. Drejer has more than 20 years of experience in the pharmaceutical industry. Before joining Symphogen, she held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her service on Symphogen’s board of directors, Dr. Drejer is also a member of the board of directors of Danisco A/S and Bioneer A/S. Her scientific experience includes research and development of drugs for the treatment of Diabetes and she was instrumental in the Insulin Analogue and Nasal Insulin programs of Novo Nordisk.
Before joining Symphogen, Mr. Feldthus served as Investment Manager at Novo A/S. Between 1996 and 1999 he was Corporate Development Manager at Novo Nordisk A/S, and prior to that he was Director of Business Development at Cheminova Agro A/S. Mr. Feldthus has extensive experience with business development, international sales, marketing, and project management and holds a M.Sc. from the Technical University of Denmark and an MBA (Sloan Fellow) from London Business School.
Gran A. Ando was born on 6 March 1949 and is a Swedish national. Dr Ando is a specialist in General Medicine and a Founding Fellow of the American College of Rheumatology in the US. Dr Ando is former Executive Vice President and President of Research & Development of Pharmacia Corporation, which was acquired by Pfizer Inc. in 2003.
In April 2003, he was appointed CEO of the Celltech Group PLC in the UK until its acquisition in 2004 by UCB.
Dr Ando is Chairman of the Board of Directors of Novo Nordisk A/S and Symphogen A/S and a member of the Board of Directors of Molecular Partners and Archimedes Pharma.
Dr Ando serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd. He is also a member of the Scientific Advisory Board of Bausch + Lomb.
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology focussed R&D company, where he served as Chief Executive Officer for eight years.
Prior to that, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc, Symphogen A/s and is Non-Executive Chairman of Bioventix plc.
Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University.
Dr. Haurum received a D.Phil. in immunology from the Institute of Molecular Medicine, University of Oxford. Subsequently, he took up a position as Assistant Professor at the Danish Cancer Society and completed his medical training. He has extensive research experience in molecular immunology and biochemistry and has published more than 35 articles. He has served as a consultant for several Danish biotech companies, and holds a Scandinavian International Management Institute (SIMI) diploma in Managing Medical Product Innovation